| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
Codrituzumab manufacturers
- Codrituzumab
-
- $147.00
-
2026-07-09
- CAS:1365267-33-9
- Purity: > 95%
- Supply Ability: 10g
|
| | Codrituzumab Basic information |
| Product Name: | Codrituzumab | | Synonyms: | Codrituzumab;Research Grade Codrituzumab(DHE84601);Codrituzumab (anti-GPC3);RG-7686|||RO5137382|||GC33;Research Grade Codrituzumab;Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) | | CAS: | 1365267-33-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Codrituzumab Structure]() |
| | Codrituzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Codrituzumab Usage And Synthesis |
| Uses | Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth[1][2][3][4]. | | References | [1] Mika Endo, et al. Abstract 2747: Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1 monoclonal antibody promotes antitumor effects. Cancer Res (2018) 78 (13_Supplement): 2747.
[2] Chen G, et al. Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget. 2018 Jan 2;9(12):10436-10444. DOI:10.18632/oncotarget.23830
[3] Carrasquillo JA, et al. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res. 2018 Mar 5;8(1):20. DOI:10.1186/s13550-018-0374-8
[4] Abou-Alfa GK, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016 Aug;65(2):289-95. DOI:10.1016/j.jhep.2016.04.004 |
| | Codrituzumab Preparation Products And Raw materials |
|